Glenmark Pharma nets $170m from unusual CB
India’s Glenmark Pharmaceuticals printed its first convertible bond in more than a decade on Tuesday, raising $170m with an unusual offering that managed to pull in decent interest from investors.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ 4 capital markets databases
- ✔ Daily newsletters across markets and asset classes
- ✔ 2 weekly podcasts